These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy].
    Author: Chen MF, Li RC, Chen CH, Gao XC.
    Journal: Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):718-9, 722. PubMed ID: 15958319.
    Abstract:
    OBJECTIVE: To observe the therapeutic effects of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy. METHODS: Eighty-five patient with liver cirrhosis complicated by hepatic encephalopathy were divided into therapy group (n=45) and control group (n=40). Patients in the control group were treated with routine comprehensive therapy, and those in the therapy group received additional intravenous administration with 40 ml L-ornithine-L-aspartate in 250 ml 10% glucose and saline (once daily, 7 days for a treatment course). RESULTS: L-ornithine-L-aspartase significantly decreased blood ammonia and improved hepatic function (P<0.05 or 0.01). The therapeutic effects of therapy group was better than that of the control group (P<0.05), and no significant side effect was observed in L-ornithine-L-aspartate treatment. CONCLUSION: L-ornithine-L-aspartate is effective for hepatic encephalopathy and has not obvious side effect.
    [Abstract] [Full Text] [Related] [New Search]